FOXO1 and diabetic kidney disease: Atrasentan, an antagonist of endothelin 1 receptor subtype A (ETA), was able to ameliorate diabetic kidney disease, by downregulating miR-21 expression, enhancing Foxo1 expression and upregulating autophagy (Wang J. et al., 2019).